PT  - JOURNAL ARTICLE
AU  - Toniolo, S
AU  - Zhao, S
AU  - Scholcz, A
AU  - Amein, B
AU  - Ganse-Dumrath, A
AU  - Heslegrave, A J
AU  - Thompson, S
AU  - Manohar, S
AU  - Zetterberg, H
AU  - Husain, M
TI  - Digital cognitive test performance and relationship to plasma biomarkers in Alzheimer’s disease
AID  - 10.1101/2023.08.21.23293786
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.08.21.23293786
4099  - http://medrxiv.org/content/early/2023/08/22/2023.08.21.23293786.short
4100  - http://medrxiv.org/content/early/2023/08/22/2023.08.21.23293786.full
AB  - A major limitation in current Alzheimer’s disease (AD) research is the lack of the ability to measure cognitive performance at scale—robustly, remotely, and frequently. For the purposes of screening, recruitment, stratification, and longitudinal follow-up in clinical trials, there are no established online digital platforms validated against plasma biomarkers of AD. Here we report findings using a novel web-based platform that assessed different cognitive functions in AD patients (N=46) and elderly controls (N=53) who were also assessed for plasma biomarkers of AD (amyloid β42/40 ratio, pTau181, GFAP, NfL). Their performance was compared to a second, larger group of elderly controls (N=256). AD patients were significantly impaired across all digital cognitive tests, with performance correlating with plasma biomarker levels, particularly pTau181. These findings show how online testing can now be deployed in AD patients to measure cognitive function effectively and related to blood biomarkers of the disease.Competing Interest StatementH.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). The other authors declare no financial or non-financial competing interests.Funding StatementThis research was supported by funding from the Wellcome Trust and NIHR Oxford Health Biomedical Research Centre. S.T., S.Z. and M.H. were funded by the Wellcome Trust (206330/Z/17/Z). The project was further supported by a Guarantors of Brain post-doctoral fellowship to S.T.. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen for Gamla Tjanarinnor, Hjarnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme - Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). The funder played no role in study design, data collection, analysis and interpretation of data, or the writing of this manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was granted by the University of Oxford ethics committee (IRAS ID: 248379, Ethics Approval Reference: 18/SC/0448). All participants gave written informed consent prior to the start of the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes